Free Trial
→ $2 Trillion Disappears Because of Fed's Secretive New Move (From Stansberry Research) (Ad) Buy COGT Stock  Free COGT Stock Alerts

Cogent Biosciences (COGT) Financials

Cogent Biosciences logo
$4.37 +0.10 (+2.34%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$4.36 0.00 (-0.11%)
As of 04/17/2025 05:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Cogent Biosciences

Annual Income Statements for Cogent Biosciences

This table shows Cogent Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -140 -192 -256
Consolidated Net Income / (Loss)		 -140 -192 -256
Net Income / (Loss) Continuing Operations		 -142 -194 -256
Total Pre-Tax Income 		-142 -194 -256
Total Operating Income		 -148 -208 -276
Total Gross Profit		 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 148 208 276
Selling, General & Admin Expense		 26 34 43
Research & Development Expense		 122 174 233
Total Other Income / (Expense), net		 7.60 16 20
Interest & Investment Income		 3.99 13 18
Other Income / (Expense), net		 2.25 0.94 1.99
Basic Earnings per Share		 ($433.56) ($488.17) ($2,426.26)
Weighted Average Basic Shares Outstanding		 58.83M 79.74M 103.94M
Diluted Earnings per Share		 ($433.56) ($488.17) ($2,426.26)
Weighted Average Diluted Shares Outstanding		 58.83M 79.74M 103.94M
Weighted Average Basic & Diluted Shares Outstanding		 69.95M 103.91M 113.85M

Quarterly Income Statements for Cogent Biosciences

This table shows Cogent Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders		 -35 -40 -39 -44 -55 -54 -58 -59 -71 -68
Consolidated Net Income / (Loss)		 -35 -40 -39 -44 -55 -54 -58 -59 -71 -68
Net Income / (Loss) Continuing Operations		 -35 -41 -39 -44 -55 -56 -58 -59 -71 -68
Total Pre-Tax Income 		-35 -41 -39 -44 -55 -56 -58 -59 -71 -68
Total Operating Income		 -37 -44 -43 -47 -60 -58 -62 -64 -75 -74
Total Operating Expenses		 37 44 43 47 60 58 62 64 75 74
Selling, General & Admin Expense		 6.89 7.00 7.20 8.21 9.45 9.51 9.70 10 12 12
Research & Development Expense		 30 37 36 39 50 49 53 54 64 62
Total Other Income / (Expense), net		 1.76 4.13 4.65 3.01 4.20 3.86 4.06 5.44 4.78 5.81
Interest & Investment Income		 1.50 2.11 2.27 2.74 4.20 3.87 4.06 5.39 4.78 3.86
Other Income / (Expense), net		 0.26 0.66 2.38 0.27 0.00 -1.71 -0.00 0.04 0.00 1.95
Basic Earnings per Share		 ($0.50) ($0.67) ($0.55) ($0.59) ($0.64) ($486.39) ($0.62) ($0.59) ($0.64) ($2,424.41)
Weighted Average Basic Shares Outstanding		 69.58M 58.83M 70.73M 74.75M 86.17M 79.74M 94.80M 99.24M 110.17M 103.94M
Diluted Earnings per Share		 ($0.50) ($0.67) ($0.55) ($0.59) ($0.64) ($486.39) ($0.62) ($0.59) ($0.64) ($2,424.41)
Weighted Average Diluted Shares Outstanding		 69.58M 58.83M 70.73M 74.75M 86.17M 79.74M 94.80M 99.24M 110.17M 103.94M
Weighted Average Basic & Diluted Shares Outstanding		 69.89M 69.95M 70.95M 85.47M 86.12M 103.91M 95.61M 109.45M 110.46M 113.85M

Annual Cash Flow Statements for Cogent Biosciences

This table details how cash moves in and out of Cogent Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Change in Cash & Equivalents		 -80 -88 45
Net Cash From Operating Activities		 -119 -154 -208
Net Cash From Continuing Operating Activities		 -119 -153 -208
Net Income / (Loss) Continuing Operations		 -140 -192 -256
Consolidated Net Income / (Loss)		 -140 -192 -256
Depreciation Expense		 0.84 2.27 2.45
Amortization Expense		 3.40 -5.17 -5.72
Non-Cash Adjustments To Reconcile Net Income		 18 30 40
Changes in Operating Assets and Liabilities, net		 -0.61 12 12
Net Cash From Investing Activities		 -125 -98 38
Net Cash From Continuing Investing Activities		 -125 -98 38
Purchase of Property, Plant & Equipment		 -6.86 -2.80 -0.57
Purchase of Investments		 -178 -349 -256
Sale and/or Maturity of Investments		 60 254 294
Net Cash From Financing Activities		 164 164 214
Net Cash From Continuing Financing Activities		 164 164 214
Issuance of Common Equity		 162 163 214
Other Financing Activities, net		 1.26 0.97 0.20

Quarterly Cash Flow Statements for Cogent Biosciences

This table details how cash moves in and out of Cogent Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents		 -185 -0.68 21 52 -128 -34 163 -128 8.83 1.12
Net Cash From Operating Activities		 -34 -29 -40 -32 -38 -44 -53 -43 -52 -61
Net Cash From Continuing Operating Activities		 -34 -29 -40 -32 -38 -44 -53 -43 -52 -61
Net Income / (Loss) Continuing Operations		 -35 -40 -39 -44 -55 -54 -58 -59 -71 -68
Consolidated Net Income / (Loss)		 -35 -40 -39 -44 -55 -54 -58 -59 -71 -68
Depreciation Expense		 0.26 0.42 0.53 0.56 0.58 0.60 0.60 0.61 0.62 0.63
Amortization Expense		 3.00 -0.67 -0.85 -0.08 1.18 -5.42 -0.93 3.06 -5.72 -2.12
Non-Cash Adjustments To Reconcile Net Income		 4.23 5.04 5.85 7.16 8.76 8.06 9.39 10 10 9.98
Changes in Operating Assets and Liabilities, net		 -6.86 5.42 -6.46 4.37 6.89 7.44 -3.24 2.58 13 -1.13
Net Cash From Investing Activities		 -152 28 60 -78 -91 10 1.04 -85 60 62
Net Cash From Continuing Investing Activities		 -152 28 60 -78 -91 10 1.04 -85 60 62
Purchase of Property, Plant & Equipment		 -3.31 -1.97 -1.10 -1.26 -0.12 -0.32 -0.07 -0.15 -0.28 -0.08
Purchase of Investments		 -148 -30 -59 -126 -112 -51 -73 -150 -19 -13
Sale and/or Maturity of Investments		 - 60 120 50 22 62 74 66 80 74
Net Cash From Financing Activities		 0.99 0.32 0.45 162 1.00 - 214 -0.26 0.62 0.03
Net Cash From Continuing Financing Activities		 0.99 0.32 0.45 162 1.00 - 214 -0.26 0.62 0.03
Issuance of Common Equity		 0.05 - 0.31 162 0.27 - 214 -0.37 0.56 -0.00
Other Financing Activities, net		 0.94 0.32 0.13 0.10 0.73 - 0.00 0.11 0.06 0.03

Annual Balance Sheets for Cogent Biosciences

This table presents Cogent Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Total Assets		 301 313 328
Total Current Assets		 265 271 296
Cash & Equivalents		 140 53 98
Restricted Cash		 1.26 0.00 0.00
Short-Term Investments		 119 212 189
Prepaid Expenses		 4.44 5.06 9.40
Plant, Property, & Equipment, net		 7.78 8.34 6.47
Total Noncurrent Assets		 28 34 25
Long-Term Investments		 0.00 7.46 0.00
Other Noncurrent Operating Assets		 28 27 25
Total Liabilities & Shareholders' Equity		 301 313 328
Total Liabilities		 45 56 72
Total Current Liabilities		 27 38 56
Accounts Payable		 5.84 11 12
Accrued Expenses		 18 26 42
Other Current Liabilities		 3.12 1.39 1.57
Total Noncurrent Liabilities		 18 17 16
Other Noncurrent Operating Liabilities		 18 17 16
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 256 258 256
Total Preferred & Common Equity		 256 258 256
Preferred Stock		 66 60 111
Total Common Equity		 190 198 146
Common Stock		 601 801 1,005
Retained Earnings		 -411 -604 -859
Accumulated Other Comprehensive Income / (Loss)		 -0.10 0.25 0.45

Quarterly Balance Sheets for Cogent Biosciences

This table presents Cogent Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets		 332 263 392 355 476 430 384
Total Current Assets		 296 226 335 286 442 370 342
Cash & Equivalents		 141 161 214 87 216 88 97
Short-Term Investments		 149 60 115 192 220 275 238
Prepaid Expenses		 6.07 4.75 5.12 6.91 6.16 6.76 6.01
Plant, Property, & Equipment, net		 6.54 9.03 9.10 8.64 7.82 7.36 7.02
Total Noncurrent Assets		 29 28 49 61 26 53 35
Long-Term Investments		 - - 22 34 0.00 27 10
Other Noncurrent Operating Assets		 29 28 27 27 26 26 25
Total Liabilities & Shareholders' Equity		 332 263 392 355 476 430 384
Total Liabilities		 42 40 44 53 54 57 69
Total Current Liabilities		 24 21 26 35 37 40 53
Accounts Payable		 4.09 4.17 7.16 9.87 16 8.98 15
Accrued Expenses		 14 16 17 24 20 30 36
Other Current Liabilities		 5.07 0.95 1.18 1.34 1.43 1.48 1.52
Total Noncurrent Liabilities		 18 19 18 18 17 17 16
Other Noncurrent Operating Liabilities		 18 19 18 18 17 17 16
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 290 224 348 303 422 373 315
Total Preferred & Common Equity		 290 224 348 303 422 373 315
Preferred Stock		 66 62 62 60 222 114 111
Total Common Equity		 224 161 286 243 200 259 204
Common Stock		 596 611 780 792 862 980 995
Retained Earnings		 -372 -450 -494 -549 -662 -721 -792
Accumulated Other Comprehensive Income / (Loss)		 -0.16 0.02 -0.10 -0.17 -0.04 -0.19 0.90

Annual Metrics and Ratios for Cogent Biosciences

This table displays calculated financial ratios and metrics derived from Cogent Biosciences' official financial filings.

Metric 2022 2023 2024
Growth Metrics		 - - -
Revenue Growth		 0.00% 0.00% 0.00%
EBITDA Growth		 -98.83% -48.63% -31.95%
EBIT Growth		 -99.21% -42.31% -32.22%
NOPAT Growth		 -95.68% -40.78% -32.58%
Net Income Growth		 -94.04% -37.20% -32.98%
EPS Growth		 -23,085.03% -12.60% -397.01%
Operating Cash Flow Growth		 -101.89% -29.49% -35.26%
Free Cash Flow Firm Growth		 -89.75% -29.68% -31.54%
Invested Capital Growth		 12.80% -220.43% -100.36%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -15.07% -11.36% -3.17%
EBIT Q/Q Growth		 -13.86% -8.85% -4.52%
NOPAT Q/Q Growth		 -13.96% -7.48% -5.95%
Net Income Q/Q Growth		 -11.71% -8.30% -5.60%
EPS Q/Q Growth		 -23,986.67% -23,597.57% -97,340.16%
Operating Cash Flow Q/Q Growth		 -7.85% -10.55% -8.63%
Free Cash Flow Firm Q/Q Growth		 -8.47% -7.22% -10.15%
Invested Capital Q/Q Growth		 -1,078.38% -54.65% 0.32%
Profitability Metrics		 - - -
Gross Margin		 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00%
Tax Burden Percent		 99.04% 99.12% 100.00%
Interest Burden Percent		 97.26% 93.69% 93.40%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -59.69% -74.94% -99.54%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -40.48% -56.57% -66.50%
Return on Equity Simple (ROE_SIMPLE)		 -54.84% -74.63% -99.83%
Net Operating Profit after Tax (NOPAT)		 -103 -146 -193
NOPAT Margin		 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -15.31% -17.51% -22.38%
Return On Investment Capital (ROIC_SIMPLE)		 -40.47% -56.51% -75.37%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -146 -207 -274
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -141 -210 -277
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 4.25 2.56 5.91
Price to Tangible Book Value (P/TBV)		 4.25 2.56 5.91
Price to Revenue (P/Rev)		 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.04 -1.09
Leverage Ratio		 1.13 1.20 1.25
Compound Leverage Factor		 1.10 1.12 1.17
Debt to Total Capital		 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 25.74% 23.29% 43.15%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 74.26% 76.71% 56.85%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 8.19 1.47 1.67
Noncontrolling Interest Sharing Ratio		 32.18% 24.51% 33.19%
Liquidity Ratios		 - - -
Current Ratio		 9.87 7.09 5.32
Quick Ratio		 9.66 6.96 5.15
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -104 -135 -178
Operating Cash Flow to CapEx		 -1,728.66% -5,494.42% -36,263.70%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 -4.80 -15 -31
Invested Capital Turnover		 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.70 -11 -15
Enterprise Value (EV)		 613 293 685
Market Capitalization		 808 506 862
Book Value per Share		 $2.72 $2.30 $1.32
Tangible Book Value per Share		 $2.72 $2.30 $1.32
Total Capital		 256 258 256
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -261 -273 -287
Capital Expenditures (CapEx)		 6.86 2.80 0.57
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -22 -33 -46
Debt-free Net Working Capital (DFNWC)		 238 233 241
Net Working Capital (NWC)		 238 233 241
Net Nonoperating Expense (NNE)		 37 47 63
Net Nonoperating Obligations (NNO)		 -261 -273 -287
Total Depreciation and Amortization (D&A)		 4.24 -2.90 -3.27
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($2.39) ($2.42) ($2,426.26)
Adjusted Weighted Average Basic Shares Outstanding		 58.74M 79.66M 103.94M
Adjusted Diluted Earnings per Share		 ($2.39) ($2.42) ($2,426.26)
Adjusted Weighted Average Diluted Shares Outstanding		 58.74M 79.66M 103.94M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 69.95M 103.91M 113.85M
Normalized Net Operating Profit after Tax (NOPAT)		 -103 -146 -193
Normalized NOPAT Margin		 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Cogent Biosciences

This table displays calculated financial ratios and metrics derived from Cogent Biosciences' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -78.26% -74.62% -36.43% -34.20% -73.59% -49.45% -52.36% -30.96% -39.26% -13.16%
EBIT Growth		 -90.44% -69.89% -32.90% -33.01% -62.96% -39.10% -52.75% -37.44% -26.57% -19.77%
NOPAT Growth		 -85.79% -70.61% -37.62% -31.32% -61.81% -33.11% -44.33% -36.75% -26.58% -26.63%
Net Income Growth		 -83.72% -59.03% -25.96% -26.19% -57.95% -37.22% -51.21% -33.75% -27.54% -24.95%
EPS Growth		 -4.17% -4.69% 19.12% 16.90% -28.00% -72,495.52% -12.73% 0.00% 0.00% -398.45%
Operating Cash Flow Growth		 -144.10% -41.54% -39.47% -21.21% -10.25% -49.86% -32.93% -33.17% -36.90% -37.46%
Free Cash Flow Firm Growth		 -43.70% -56.85% -55.78% -65.05% -3.73% 3.63% 20.46% 18.56% 1.05% -19.89%
Invested Capital Growth		 92.80% 12.80% 164.20% 66.59% -2,341.52% -220.43% -755.87% -571.81% -210.85% -100.36%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 3.54% -30.10% 4.98% -12.54% -24.77% -12.01% 3.13% 3.27% -32.69% 8.98%
EBIT Q/Q Growth		 -3.87% -17.85% 5.18% -14.59% -27.26% -0.60% -4.12% -3.11% -17.20% 4.81%
NOPAT Q/Q Growth		 -2.69% -18.80% 1.16% -8.90% -26.54% 2.27% -7.17% -3.18% -17.13% 2.23%
Net Income Q/Q Growth		 -0.39% -12.99% 2.60% -14.23% -25.65% 1.84% -7.33% -1.03% -19.82% 3.83%
EPS Q/Q Growth		 29.58% -34.00% 17.91% -7.27% -8.47% -75,898.44% 3.13% 4.84% -8.47% -378,714.06%
Operating Cash Flow Q/Q Growth		 -30.18% 14.61% -34.38% 18.86% -18.42% -16.06% -19.19% 18.71% -21.74% -16.53%
Free Cash Flow Firm Q/Q Growth		 -35.05% -0.99% -13.31% -6.80% 15.12% 6.18% 6.48% -9.35% -3.13% -13.67%
Invested Capital Q/Q Growth		 94.52% -1,078.38% 142.62% -221.48% -300.20% -54.65% 12.77% -24.43% -85.17% 0.32%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 96.68% 100.00% 100.00% 100.00% 96.97% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 95.90% 95.10% 94.45% 94.15% 92.95% 93.54% 93.50% 91.62% 93.66% 94.62%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -51.54% -59.69% -72.04% -47.12% -59.94% -74.94% -65.70% -62.92% -78.47% -99.54%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -5,723.51% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -44.57% -40.48% -47.40% -37.69% -47.21% -56.57% -36.76% -47.54% -56.79% -66.50%
Return on Equity Simple (ROE_SIMPLE)		 -43.30% 0.00% -66.29% -45.16% -58.65% 0.00% -50.24% -60.83% -77.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -26 -31 -30 -33 -42 -41 -44 -45 -53 -52
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -3.77% -3.75% -4.03% -3.28% -4.53% -5.10% -4.46% -3.75% -5.42% -5.82%
Return On Investment Capital (ROIC_SIMPLE)		 - -11.97% - - - -15.81% - - - -20.14%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -37 -43 -41 -47 -60 -60 -62 -64 -75 -72
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -33 -43 -41 -46 -58 -65 -63 -61 -81 -73
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 4.38 4.25 4.68 2.94 3.43 2.56 2.89 3.11 5.79 5.91
Price to Tangible Book Value (P/TBV)		 4.38 4.25 4.68 2.94 3.43 2.56 2.89 3.11 5.79 5.91
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 291.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.01 -1.02 -1.00 -1.01 -1.02 -1.04 -1.02 -1.03 -1.07 -1.09
Leverage Ratio		 1.12 1.13 1.14 1.14 1.16 1.20 1.14 1.14 1.20 1.25
Compound Leverage Factor		 1.08 1.08 1.08 1.07 1.08 1.12 1.07 1.04 1.12 1.18
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 22.70% 25.74% 27.87% 17.88% 19.82% 23.29% 52.60% 30.58% 35.15% 43.15%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 77.30% 74.26% 72.13% 82.12% 80.18% 76.71% 47.40% 69.42% 64.85% 56.85%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 13.20 9.32 9.46 10.26 7.65 3.02 5.10 6.61 7.59 3.71
Noncontrolling Interest Sharing Ratio		 13.51% 32.18% 34.20% 20.02% 21.23% 24.51% 44.04% 24.45% 27.63% 33.19%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 12.59 9.87 10.71 12.99 8.24 7.09 12.05 9.25 6.44 5.32
Quick Ratio		 12.28 9.66 10.43 12.79 8.04 6.96 11.88 9.08 6.32 5.15
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -31 -31 -35 -38 -32 -30 -28 -31 -32 -36
Operating Cash Flow to CapEx		 -1,040.17% -1,495.07% -3,582.68% -2,550.99% -31,380.99% -13,990.48% -75,041.43% -28,852.03% -18,565.71% -80,769.33%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -0.41 -4.80 2.04 -2.48 -9.94 -15 -13 -17 -31 -31
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 5.24 0.70 5.23 4.95 -9.53 -11 -15 -14 -21 -15
Enterprise Value (EV)		 757 613 596 551 580 293 365 530 947 685
Market Capitalization		 981 808 755 840 833 506 579 806 1,182 862
Book Value per Share		 $3.41 $2.72 $2.31 $4.03 $2.84 $2.30 $2.11 $2.71 $1.86 $1.32
Tangible Book Value per Share		 $3.41 $2.72 $2.31 $4.03 $2.84 $2.30 $2.11 $2.71 $1.86 $1.32
Total Capital		 290 256 224 348 303 258 422 373 315 256
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -290 -261 -222 -351 -313 -273 -436 -390 -346 -287
Capital Expenditures (CapEx)		 3.31 1.97 1.10 1.26 0.12 0.32 0.07 0.15 0.28 0.08
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -17 -22 -16 -21 -28 -33 -31 -33 -47 -46
Debt-free Net Working Capital (DFNWC)		 273 238 205 309 251 233 405 330 288 241
Net Working Capital (NWC)		 273 238 205 309 251 233 405 330 288 241
Net Nonoperating Expense (NNE)		 9.29 9.00 8.32 11 14 14 15 14 18 16
Net Nonoperating Obligations (NNO)		 -290 -261 -222 -351 -313 -273 -436 -390 -346 -287
Total Depreciation and Amortization (D&A)		 3.26 -0.25 -0.32 0.48 1.76 -4.83 -0.33 3.66 -5.10 -1.50
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.50) ($0.67) ($0.55) ($0.59) ($0.64) ($486.39) ($0.62) ($0.59) ($0.64) ($2,424.41)
Adjusted Weighted Average Basic Shares Outstanding		 69.58M 58.83M 70.73M 74.75M 86.17M 79.74M 94.80M 99.24M 110.17M 103.94M
Adjusted Diluted Earnings per Share		 ($0.50) ($0.67) ($0.55) ($0.59) ($0.64) ($486.39) ($0.62) ($0.59) ($0.64) ($2,424.41)
Adjusted Weighted Average Diluted Shares Outstanding		 69.58M 58.83M 70.73M 74.75M 86.17M 79.74M 94.80M 99.24M 110.17M 103.94M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($0.67) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 69.89M 69.95M 70.95M 85.47M 86.12M 103.91M 95.61M 109.45M 110.46M 113.85M
Normalized Net Operating Profit after Tax (NOPAT)		 -26 -31 -30 -33 -42 -41 -44 -45 -53 -52
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Cogent Biosciences' Financials

When does Cogent Biosciences's fiscal year end?

According to the most recent income statement we have on file, Cogent Biosciences' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Cogent Biosciences' net income changed over the last 2 years?

Cogent Biosciences' net income appears to be on an upward trend, with a most recent value of -$255.86 million in 2024, rising from -$140.24 million in 2022. The previous period was -$192.41 million in 2023.

What is Cogent Biosciences's operating income?
Cogent Biosciences's total operating income in 2024 was -$275.94 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $275.94 million
How has Cogent Biosciences revenue changed over the last 2 years?

Over the last 2 years, Cogent Biosciences' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does Cogent Biosciences have?

Cogent Biosciences' total liabilities were at $71.61 million at the end of 2024, a 28.7% increase from 2023, and a 58.9% increase since 2022.

How much cash does Cogent Biosciences have?

In the past 2 years, Cogent Biosciences' cash and equivalents has ranged from $53.23 million in 2023 to $139.89 million in 2022, and is currently $98.17 million as of their latest financial filing in 2024.

How has Cogent Biosciences' book value per share changed over the last 2 years?

Over the last 2 years, Cogent Biosciences' book value per share changed from 2.72 in 2022 to 1.32 in 2024, a change of -51.5%.


Related Companies

This page (NASDAQ:COGT) was last updated on 4/19/2025 by MarketBeat.com Staff
From Our Partners
Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsored
Elon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to Mars
Elon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...
InvestorPlace | Sponsored
Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...
Investors Alley | Sponsored
Trump to redistribute trillions of dollars
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
Amazon Shocker
Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...
Stansberry Research | Sponsored
DOGE Social Security bombshell?
Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...
Altimetry | Sponsored
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...
Golden Portfolio | Sponsored
Caught on Camera: Elon Musk’s “Area 51”
You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...
Brownstone Research | Sponsored